NCT06220617 Multi-omics Study for Early Detection of Colorectal Cancer (MOED-CRC)
| NCT ID | NCT06220617 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Zhejiang University |
| Condition | Colorectal Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,600 participants |
| Start Date | 2024-01-11 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,600 participants in total. It began in 2024-01-11 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The primary objective of the study is to screen multi-omics markers in blood samples and construct a prediction model for CRC based on liquid biopsy, and we will further optimize the prediction model by validating its clinical performance externally.
Eligibility Criteria
Inclusion Criteria for Case Arm: 1. Aged over 18 years. 2. Participants confirmed with colorectal adenocarcinoma or advanced adenoma through colonoscopy and pathological examination. 3. Provision of informed consent prior to any study specific procedures, sampling, and analyses. Inclusion Criteria for Control Arm: 1. Individuals of "General risk arm" should meet all the following criteria: 1. No history of colorectal adenomas or sessile serrated polyps. 2. No history of inflammatory bowel disease (8-10 years ). 3. No family history (first-degree relatives) of colorectal cancer. 2. Individuals of "High-risk arm" should meet at least one of the following criteria: 1. Asia-Pacific Colorectal Screening (APC) score ≥ 3. 2. Family history (first-degree relatives) of colorectal cancer. 3. History of positive fecal occult blood test. 4. Any 2 of the following: chronic diarrhea, chronic constipation, mucous bloody stools, history of psychological stimulation, history of chronic appendicitis or appendectomy, history of chronic biliary disease or cholecystectomy. 5. Individuals with inflammatory bowel disease. 3. All participants must be confirmed not to have colorectal malignancy or advanced adenomas through colonoscopy. 4. Provision of informed consent prior to any study specific procedures, sampling, and analyses. Exclusion Criteria: 1. History of other malignant tumors (excluding non-melanoma skin cancer). 2. Prior or related treatments previously (including colorectal cancer or advanced adenoma surgery, endoscopic treatment, chemotherapy, targeted therapy, immunotherapy, radiation, neoadjuvant therapy, etc.). 3. Patients with hereditary colorectal diseases (including Lynch syndrome, familial CRC type X (FCCX), familial adenomatous polyposis (FAP), MUTHY-associated polyposis (MAP), Peutz-Jeghers syndrome (PJS), juvenile polyposis syndrome (JPS), serrated polyposis syndrome (SPS), etc.). 4. Usage of anti-tumor drugs such as methotrexate, cyclophosphamide, mercaptopurine, and bendamustine for other diseases within 30 days before blood collection. 5. Prior blood transfusion (including blood components) within the past 2 weeks. 6. Prior organ transplantation, bone marrow transplantation, or stem cell transplantation. 7. Pregnancy women. 8. Prior or current anti-infection treatment within 14 days before blood collection. 9. Inability to comply with study procedures such as blood collection and related examinations. 10. Deemed unsuitable for participation in the clinical trial by the investigator.
Contact & Investigator
Kefeng Ding, MD
PRINCIPAL INVESTIGATOR
Second Affiliated Hospital, Zhejiang University, School of Medicine
Frequently Asked Questions
Who can join the NCT06220617 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Colorectal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06220617 currently recruiting?
Yes, NCT06220617 is actively recruiting participants. Contact the research team at dingkefeng@zju.edu.cn for enrollment information.
Where is the NCT06220617 trial being conducted?
This trial is being conducted at Hangzhou, China, Guangzhou, China, Kunming, China, Nanjing, China and 2 additional locations.
Who is sponsoring the NCT06220617 clinical trial?
NCT06220617 is sponsored by Zhejiang University. The principal investigator is Kefeng Ding, MD at Second Affiliated Hospital, Zhejiang University, School of Medicine. The trial plans to enroll 3,600 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.